Germline testing for inherited risk of myeloid blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm study will enroll about 200 adults with histologically confirmed myeloid malignancies or recent bone marrow failure to undergo germline testing using the investigational MyeloGen Gene Panel. Study procedures include eligibility screening, in‑clinic visits, questionnaires, and a punch skin biopsy to obtain germline DNA. The protocol aims to determine how feasible it is to incorporate routine germline testing into clinical care for people with blood cancers regardless of their personal or family history. The Broad Clinical Laboratory sponsors the testing and the trial is conducted at Dana‑Farber Cancer Institute.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of 18 years or older
* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
* Ability to understand and provide a signed and completed consent document in English.

Exclusion Criteria:

* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Christopher R Reilly, MD — Dana-Farber Cancer Institute
• Study coordinator: Christopher R Reilly, MD
• Email: Christopherr_reilly@dfci.harvard.edu
• Phone: 407-443-6243

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Sirolimus for ApoE4 Carriers: Testing Brain Blood Flow in Women 45-65

  Researchers will test whether sirolimus can improve brain blood flow in healthy ApoE4-positive women ages 45 to 65 compared with a placebo.

  Recruiting Phase 1 University of Missouri-Columbia · Columbia, Missouri · NCT07728175

• BG-75202 alone or with other drugs in myeloid malignancies

  This study tests BG-75202, a KAT6A/B inhibitor, alone and with other agents to see if it is safe and potentially helpful for adults with myeloid malignancies.

  Recruiting at 17 sites Phase 1 BeOne Medicines · Concord, New South Wales and 16 other locations · NCT07619287

• RSK1 Inhibitor PMD-026 in myeloid malignancies

  A first-in-human test of PMD-026, an oral drug that blocks RSK1, to see if it is safe and can help reduce spleen size and symptoms in people with myelofibrosis and related myeloid conditions.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07379125

• Considering allogeneic stem cell transplant using digital patient stories and values tools

  This program will test whether digital patient stories plus values-clarification exercises help adults with myeloid cancers who are deciding about allogeneic hematopoietic cell transplantation make choices that fit their goals.

  Recruiting University of Rochester · Rochester, New York · NCT07263074

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.